Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 ...
Celcuity (CELC) is making strides with its lead therapeutic candidate, Gedatolisib, currently in Phase 3 clinical trials. It shows promising potential as a first-line treatment for HR+/HER2- advanced ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Celcuity Inc. retains a 'Buy' rating as gedatolisib advances toward a likely 2026 FDA approval and commercial launch. VIKTORIA-1 phase 3 data show gedatolisib delivers superior progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results